Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Tumor Boards
Colleague Insights
Living Resources
Conferences
Nursing Perspectives
Video Expert Opinion
Sign in
Join now
featured
Published in Metastatic Breast Cancer

Expert Opinion / Cases · March 16, 2022

65-Year-Old Postmenopausal Woman With Recurrent Metastatic ER+ PR– HER2– Lobular Breast Cancer

Ana Sandoval Leon MD

 

 Save  Recommend
 Share

Discuss This item Follow

No comments yet, be the first to start the discussion!

  • Jose A Garcia-Saenz

    Mar 18, 2022

    Consider a Clinical Trial otherwise Alpelisib, either with FUL or NSAI as ET backbone

  • THIRU PRASANNA

    Mar 18, 2022

    Paclitaxel

  • Sandro Barni

    Mar 18, 2022

    Continue Fulvestrant and change Abemaciclib to Alpelisib

  • satadru ray

    Mar 18, 2022

    Fulvestrant with alpelisib

  • nadire kucukoztas

    Mar 18, 2022

    Since the patient is hormone resistant, I recommend capecitabine treatment to the patient.

  • luis betancourt

    Mar 18, 2022

    test BRCA

  • Feng-Jen Chen

    Mar 18, 2022

    Continue Fulvestrant and change Abemaciclib to Alpelisib

  • mindy bohrer

    Mar 18, 2022

    fulvestrant plus alpelisib

  • hamid rezvani

    Mar 18, 2022

    continue fulvestrant and replace abemaciclib for alpelisib

  • pramod kumar julka

    Mar 19, 2022

    Alpelisib with fulvestrant

  • Claus Schlotter Prof.Dr.med.

    Mar 19, 2022

    nab-Paclitaxel weekly

  • Luca Licata

    Mar 19, 2022

    The patient had a disease progression 6 months after starting the 1st line endocrine-based therapy (i.e. primary endocrine resistance) and her best response to the 2nd line endocrine-based therapy was a stable disease. I’m not sure that another endocrine-based therapy might be her best option. I would opt for paclitaxel (an oral therapy like capecitabine it’s not the best option in the case of peritoneal metastases and the possible risk of bowel obstruction)

  • Bogdan Cristian Dinu

    Mar 21, 2022

    biopsy if it is not so harmfull from peritoneum end adapt treatment afterthat , usually the bone mets are different biology from visceral secondary lesions.

  • Nov 26, 2024

    Pending Moderator approval.
    Delete

Further Reading

Most Read This Week

Recently Updated